The term antibiotic was first used in 1942 by Selman Waksman and his collaborators in journal articles to describe any substance produced by a microorganism that is antagonistic to the growth of other microorganisms in high dilution. This definition excluded substances that kill bacteria but that are not produced by microorganisms (such as gastric juices and hydrogen peroxide). It also excluded synthetic antibacterial compounds such as the sulfonamides. Many antibacterial compounds are relatively small molecules with a molecular weight of less than 2000 atomic mass units.
With advances in medicinal chemistry, most modern antibacterials are semisynthetic modifications of various natural compounds. These include, for example, the beta-lactam antibiotics, which include the penicillins (produced by fungi in the genus Penicillium), the cephalosporins, and the carbapenems. Compounds that are still isolated from living organisms are the aminoglycosides, whereas other antibacterials—for example, the sulfonamides, the quinolones, and the oxazolidinones—are produced solely by chemical synthesis. In accordance with this, many antibacterial compounds are classified on the basis of chemical/biosynthetic origin into natural, semisynthetic, and synthetic. Another classification system is based on biological activity; in this classification, antibacterials are divided into two broad groups according to their biological effect on microorganisms: Bactericidal agents kill bacteria, and bacteriostatic agents slow down or stall bacterial growth.
- 1 History
- 2 Medical uses
- 3 Pharmacodynamics
- 4 Classes
- 5 Production
- 6 Administration
- 7 Side-effects
- 8 Drug-drug interactions
- 9 Resistance
- 10 Alternatives
- 11 Status of new antibiotics development (2013)
- 12 See also
- 13 References
- 14 External links
Before the early 20th century, treatments for infections were based primarily on medicinal folklore. Mixtures with antimicrobial properties that were used in treatments of infections were described over 2000 years ago. Many ancient cultures, including the ancient Egyptians and ancient Greeks, used specially selected mold and plant materials and extracts to treat infections. More recent observations made in the laboratory of antibiosis between micro-organisms led to the discovery of natural antibacterials produced by microorganisms. Louis Pasteur observed, "if we could intervene in the antagonism observed between some bacteria, it would offer perhaps the greatest hopes for therapeutics". The term 'antibiosis', meaning "against life," was introduced by the French bacteriologist Jean Paul Vuillemin as a descriptive name of the phenomenon exhibited by these early antibacterial drugs. Antibiosis was first described in 1877 in bacteria when Louis Pasteur and Robert Koch observed that an airborne bacillus could inhibit the growth of Bacillus anthracis. These drugs were later renamed antibiotics by Selman Waksman, an American microbiologist, in 1942. Synthetic antibiotic chemotherapy as a science and development of antibacterials began in Germany with Paul Ehrlich in the late 1880s. Ehrlich noted that certain dyes would color human, animal, or bacterial cells, whereas others did not. He then proposed the idea that it might be possible to create chemicals that would act as a selective drug that would bind to and kill bacteria without harming the human host. After screening hundreds of dyes against various organisms, he discovered a medicinally useful drug, the synthetic antibacterial Salvarsan now called arsphenamine.
The effects of some types of mold on infection had been noticed many times over the course of history (see: History of penicillin). In 1928 Alexander Fleming noticed the same effect in a petri dish where a number of disease-causing bacteria were killed by a fungus of the genus Penicillium. Fleming postulated that the effect is mediated by an antibacterial compound he named penicillin, and that its antibacterial properties could be exploited for chemotherapy. He initially characterized some of its biological properties, and attempted to use a crude preparation to treat some infections, but he was unable to pursue its further development without the aid of trained chemists.
The first sulfonamide and first commercially available antibacterial, Prontosil, was developed by a research team led by Gerhard Domagk in 1932 at the Bayer Laboratories of the IG Farben conglomerate in Germany. Domagk received the 1939 Nobel Prize for Medicine for his efforts. Prontosil had a relatively broad effect against Gram-positive cocci, but not against enterobacteria. Research was stimulated apace by its success. The discovery and development of this sulfonamide drug opened the era of antibacterials.
In 1939, coinciding with the start of World War II, Rene Dubos reported the discovery of the first naturally derived antibiotic, tyrothricin, a compound of 20% gramicidin and 80% tyrocidine, from B. brevis. It was one of the first commercially manufactured antibiotics universally and was very effective in treating wounds and ulcers during World War II. Gramicidin, however, could not be used systemically because of toxicity. Tyrocidine also proved too toxic for systemic usage. Research results obtained during that period were not shared between the Axis and the Allied powers during the war.
Florey and Chain succeeded in purifying the first penicillin, penicillin G, in 1942, but it did not become widely available outside the Allied military before 1945. The chemical structure of penicillin was determined by Dorothy Crowfoot Hodgkin in 1945. Purified penicillin displayed potent antibacterial activity against a wide range of bacteria and had low toxicity in humans. Furthermore, its activity was not inhibited by biological constituents such as pus, unlike the synthetic sulfonamides. The discovery of such a powerful antibiotic was unprecedented, and the development of penicillin led to renewed interest in the search for antibiotic compounds with similar efficacy and safety. For their successful development of penicillin, which Fleming had accidentally discovered but could not develop himself, as a therapeutic drug, Ernst Chain and Howard Florey shared the 1945 Nobel Prize in Medicine with Fleming. Florey credited Dubos with pioneering the approach of deliberately and systematically searching for antibacterial compounds, which had led to the discovery of gramicidin and had revived Florey's research in penicillin.
The term "antibacterial" derives from Greek ἀντί (anti), "against" + βακτήριον (baktērion), diminutive of βακτηρία (baktēria), "staff, cane", because the first ones to be discovered were rod-shaped, and the term "antibiotic" derives from anti + βιωτικός (biōtikos), "fil for life, lively", which comes from βίωσις (biōsis), "way of life", and that from βίος (bios), "life".
- Prevention of infection
The successful outcome of antimicrobial therapy with antibacterial compounds depends on several factors. These include host defense mechanisms, the location of infection, and the pharmacokinetic and pharmacodynamic properties of the antibacterial. A bactericidal activity of antibacterials may depend on the bacterial growth phase, and it often requires ongoing metabolic activity and division of bacterial cells. These findings are based on laboratory studies, and in clinical settings have also been shown to eliminate bacterial infection. Since the activity of antibacterials depends frequently on its concentration, in vitro characterization of antibacterial activity commonly includes the determination of the minimum inhibitory concentration and minimum bactericidal concentration of an antibacterial. To predict clinical outcome, the antimicrobial activity of an antibacterial is usually combined with its pharmacokinetic profile, and several pharmacological parameters are used as markers of drug efficacy.
Antibacterial antibiotics are commonly classified based on their mechanism of action, chemical structure, or spectrum of activity. Most target bacterial functions or growth processes. Those that target the bacterial cell wall (penicillins and cephalosporins) or the cell membrane (polymyxins), or interfere with essential bacterial enzymes (rifamycins, lipiarmycins, quinolones, and sulfonamides) have bactericidal activities. Those that target protein synthesis (macrolides, lincosamides and tetracyclines) are usually bacteriostatic (with the exception of bactericidal aminoglycosides). Further categorization is based on their target specificity. "Narrow-spectrum" antibacterial antibiotics target specific types of bacteria, such as Gram-negative or Gram-positive bacteria, whereas broad-spectrum antibiotics affect a wide range of bacteria. Following a 40-year hiatus in discovering new classes of antibacterial compounds, four new classes of antibacterial antibiotics have been brought into clinical use: cyclic lipopeptides (such as daptomycin), glycylcyclines (such as tigecycline), oxazolidinones (such as linezolid), and lipiarmycins (such as fidaxomicin).
Since the first pioneering efforts of Florey and Chain in 1939, the importance of antibiotics, including antibacterials, to medicine has led to intense research into producing antibacterials at large scales. Following screening of antibacterials against a wide range of bacteria, production of the active compounds is carried out using fermentation, usually in strongly aerobic conditions.
Oral antibacterials are orally ingested, whereas intravenous administration may be used in more serious cases , such as deep-seated systemic infections. Antibiotics may also sometimes be administered topically, as with eye drops or ointments.
Antibacterials are screened for any negative effects on humans or other mammals before approval for clinical use, and are usually considered safe and most are well-tolerated. However, some antibacterials have been associated with a range of adverse effects. Side-effects range from mild to very serious depending on the antibiotics used, the microbial organisms targeted, and the individual patient. Safety profiles of newer drugs are often not as well-established as for those that have a long history of use. Adverse effects range from fever and nausea to major allergic reactions, including photodermatitis and anaphylaxis. Common side-effects include diarrhea, resulting from disruption of the species composition in the intestinal flora, resulting, for example, in overgrowth of pathogenic bacteria, such as Clostridium difficile. Antibacterials can also affect the vaginal flora, and may lead to overgrowth of yeast species of the genus Candida in the vulvo-vaginal area. Additional side-effects can result from interaction with other drugs, such as elevated risk of tendon damage from administration of a quinolone antibiotic with a systemic corticosteroid. Some scientists have hypothesized that the indiscriminate use of antibiotics alter the host microbiota and this has been associated with chronic disease.
Birth control pills
The majority of studies indicate antibiotics do not interfere with contraceptive pills, such as clinical studies that suggest the failure rate of contraceptive pills caused by antibiotics is very low (about 1%). In cases where antibacterials have been suggested to affect the efficiency of birth control pills, such as for the broad-spectrum antibacterial rifampicin, these cases may be due to an increase in the activities of hepatic liver enzymes' causing increased breakdown of the pill's active ingredients. Effects on the intestinal flora, which might result in reduced absorption of estrogens in the colon, have also been suggested, but such suggestions have been inconclusive and controversial. Clinicians have recommended that extra contraceptive measures be applied during therapies using antibacterials that are suspected to interact with oral contraceptives.
- "It is sensible to avoid drinking alcohol when taking medication. However, it is unlikely that drinking alcohol in moderation will cause problems if you are taking most common antibiotics. However, there are specific types of antibiotics with which alcohol should be avoided completely, because of serious side-effects."
Therefore, potential risks of side-effects and effectiveness depend on the type of antibacterial administered. Despite the lack of a categorical counterindication, the belief that alcohol and antibacterials should never be mixed is widespread.
Antibacterials such as metronidazole, tinidazole, cephamandole, latamoxef, cefoperazone, cefmenoxime, and furazolidone, cause a disulfiram-like chemical reaction with alcohol by inhibiting its breakdown by acetaldehyde dehydrogenase, which may result in vomiting, nausea, and shortness of breath.
Other effects of alcohol on antibacterial activity include altered activity of the liver enzymes that break down the antibacterial compound. In addition, serum levels of doxycycline and erythromycin succinate[clarification needed] two bacteriostatic antibacterials (see above) may be reduced by alcohol consumption, resulting in reduced efficacy and diminished pharmacotherapeutic effect.
The emergence of resistance of bacteria to antibacterial drugs is a common phenomenon. Emergence of resistance often reflects evolutionary processes that take place during antibacterial drug therapy. The antibacterial treatment may select for bacterial strains with physiologically or genetically enhanced capacity to survive high doses of antibacterials. Under certain conditions, it may result in preferential growth of resistant bacteria, while growth of susceptible bacteria is inhibited by the drug. For example, antibacterial selection for strains having previously acquired antibacterial-resistance genes was demonstrated in 1943 by the Luria–Delbrück experiment. Antibacterials such as penicillin and erythromycin, which used to have high efficacy against many bacterial species and strains, have become less effective, because of increased resistance of many bacterial strains.
Resistance may take the form of biodegredation of pharmaceuticals, such as sulfamethazine-degrading soil bacteria introduced to sulfamethazine through medicated pig feces. The survival of bacteria often results from an inheritable resistance, but the growth of resistance to antibacterials also occurs through horizontal gene transfer. Horizontal transfer is more likely to happen in locations of frequent antibiotic use.
Antibacterial resistance may impose a biological cost, thereby reducing fitness of resistant strains, which can limit the spread of antibacterial-resistant bacteria, for example, in the absence of antibacterial compounds. Additional mutations, however, may compensate for this fitness cost and can aid the survival of these bacteria.
Paleontological data show that both antibiotics and antibiotic resistance are ancient compounds and mechanisms. Natural antibiotics (produced by microorganisms to compete against other microorganisms), however, are evolutionarily robust; i.e., microorganisms are often unable to develop resistance against them. Molecular data confirm this observation, showing that the evolution of bacterial proteins targeted by antibiotics is highly constrained compared with the evolution of other proteins. For example, mutations in genes coding for antibiotics-targeted proteins tend to be deleterious, making these genes subject to strong purifying selection, which stringently maintains the sequence and structure of their cognate proteins.
Several molecular mechanisms of antibacterial resistance exist. Intrinsic antibacterial resistance may be part of the genetic makeup of bacterial strains. For example, an antibiotic target may be absent from the bacterial genome. Acquired resistance results from a mutation in the bacterial chromosome or the acquisition of extra-chromosomal DNA. Antibacterial-producing bacteria have evolved resistance mechanisms that have been shown to be similar to, and may have been transferred to, antibacterial-resistant strains. The spread of antibacterial resistance often occurs through vertical transmission of mutations during growth and by genetic recombination of DNA by horizontal genetic exchange. For instance, antibacterial resistance genes can be exchanged between different bacterial strains or species via plasmids that carry these resistance genes. Plasmids that carry several different resistance genes can confer resistance to multiple antibacterials. Cross-resistance to several antibacterials may also occur when a resistance mechanism encoded by a single gene conveys resistance to more than one antibacterial compound.
Antibacterial-resistant strains and species, sometimes referred to as "superbugs", now contribute to the emergence of diseases that were for a while well-controlled. For example, emergent bacterial strains causing tuberculosis (TB) that are resistant to previously effective antibacterial treatments pose many therapeutic challenges. Every year, nearly half a million new cases of multidrug-resistant tuberculosis (MDR-TB) are estimated to occur worldwide. For example, NDM-1 is a newly identified enzyme conveying bacterial resistance to a broad range of beta-lactam antibacterials. The United Kingdom's Health Protection Agency has stated that "most isolates with NDM-1 enzyme are resistant to all standard intravenous antibiotics for treatment of severe infections."
The first rule of antibiotics is try not to use them, and the second rule is try not to use too many of them.—Paul L. Marino, The ICU Book
Inappropriate antibacterial treatment and overuse of antibiotics have contributed to the emergence of antibacterial-resistant bacteria. Self prescription of antibacterials is an example of misuse. Many antibacterials are frequently prescribed to treat symptoms or diseases that do not respond to antibacterial therapy or are likely to resolve without treatment, or incorrect or suboptimal antibacterials are prescribed for certain bacterial infections. The overuse of antibacterials, like penicillin and erythromycin, have been associated with emerging antibacterial resistance since the 1950s. Widespread usage of antibacterial drugs in hospitals has also been associated with increases in bacterial strains and species that no longer respond to treatment with the most common antibacterials.
Common forms of antibacterial misuse include excessive use of prophylactic antibiotics in travelers and failure of medical professionals to prescribe the correct dosage of antibacterials on the basis of the patient's weight and history of prior use. Other forms of misuse include failure to take the entire prescribed course of the antibacterial, incorrect dosage and administration, or failure to rest for sufficient recovery. Inappropriate antibacterial treatment, for example, is the prescription of antibacterials to treat viral infections such as the common cold. One study on respiratory tract infections found "physicians were more likely to prescribe antibiotics to patients who appeared to expect them". Multifactorial interventions aimed at both physicians and patients can reduce inappropriate prescription of antibiotics.
Several organizations concerned with antimicrobial resistance are lobbying to eliminate the unnecessary use of antibacterials. The issues of misuse and overuse of antibiotics have been addressed by the formation of the U.S. Interagency Task Force on Antimicrobial Resistance. This task force aims to actively address antimicrobial resistance, and is coordinated by the US Centers for Disease Control and Prevention, the Food and Drug Administration (FDA), and the National Institutes of Health (NIH), as well as other US agencies. An NGO campaign group is Keep Antibiotics Working. In France, an "Antibiotics are not automatic" government campaign started in 2002 and led to a marked reduction of unnecessary antibacterial prescriptions, especially in children.
The emergence of antibacterial resistance has prompted restrictions on antibacterial use in the UK in 1970 (Swann report 1969), and the EU has banned the use of antibacterials as growth-promotional agents since 2003. Moreover, several organizations (e.g., The American Society for Microbiology (ASM), American Public Health Association (APHA) and the American Medical Association (AMA)) have called for restrictions on antibiotic use in food animal production and an end to all nontherapeutic uses. However, commonly there are delays in regulatory and legislative actions to limit the use of antibacterials, attributable partly to resistance against such regulation by industries using or selling antibacterials, and to the time required for research to test causal links between antibacterial use and resistance. Two federal bills (S.742 and H.R. 2562) aimed at phasing out nontherapeutic use of antibacterials in US food animals were proposed, but have not passed. These bills were endorsed by public health and medical organizations, including the American Holistic Nurses' Association, the American Medical Association, and the American Public Health Association (APHA).
There has been extensive use of antibiotics in animal husbandry. In the United States, the question of emergence of antibiotic-resistant bacterial strains due to use of antibiotics in livestock was raised by the U.S. Food and Drug Administration (FDA) in 1977. In March 2012, the United States District Court for the Southern District of New York, ruling in an action brought by the Natural Resources Defense Council and others, ordered the FDA to revoke approvals for the use of antibiotics in livestock, which violated FDA regulations.
The increase in bacterial strains that are resistant to conventional antibacterial therapies has prompted the development of bacterial disease treatment strategies that are alternatives to conventional antibacterials.
One strategy to address bacterial drug resistance is the discovery and application of compounds that modify resistance to common antibacterials. For example, some resistance-modifying agents may inhibit multidrug resistance mechanisms, such as drug efflux from the cell, thus increasing the susceptibility of bacteria to an antibacterial. Targets include:
- The efflux inhibitor Phe-Arg-β-naphthylamide.
- Beta-lactamase inhibitors, such as clavulanic acid and sulbactam.
Metabolic stimuli such as sugar can help eradicate a certain type of antibiotic-tolerant bacteria by keeping their metabolism active.
Phage therapy is the use of viruses that infect bacteria (i.e., phages) for the treatment of bacterial infections. Phages are common in bacterial populations and control the growth of bacteria in many environments, including in the intestine, the ocean, and the soil. Phage therapy was in use in the 1920s and 1930s in the US, Western Europe, and Eastern Europe. However, success rates of this therapy have not been firmly established, because only a limited number of clinical trials testing the efficacy of phage therapy have been conducted. These studies were performed mainly in the former Soviet Union, at the Eliava Institute of Bacteriophage, Microbiology and Virology, Republic of Georgia. The development of antibacterial-resistant bacteria has sparked renewed interest in phage therapy in Western medicine. Several companies (e.g., Intralytix, Novolytics, and Gangagen), universities, and foundations across the world now focus on phage therapies. One concern with this therapeutic strategy is the use of genetically engineered viruses, which limits certain aspects of phage therapy.
Bacteriocins are peptides that can be more readily engineered than small molecules, and are possible alternatives to conventional antibacterial compounds. Different classes of bacteriocins have different potential as therapeutic agents. Small-molecule bacteriocins (microcins and lantibiotics) are similar to the classic antibiotics; colicin-like bacteriocins possess a narrow spectrum, and require molecular diagnostics prior to therapy. Limitations of large-molecule antibacterials include reduced transport across membranes and within the human body. For this reason, they are usually applied topically or gastrointestinally.
Chelation of micronutrients that are essential for bacterial growth to restrict pathogen spread in vivo might supplement some antibacterials. For example, limiting the iron availability in the human body restricts bacterial proliferation. Many bacteria, however, possess mechanisms (such as siderophores) for scavenging iron within environmental niches in the human body, and experimental developments of iron chelators, therefore, aim to reduce iron availability specifically to bacterial pathogens.
Vaccines rely on immune modulation or augmentation. Vaccination either excites or reinforces the immune competency of a host to ward off infection, leading to the activation of macrophages, the production of antibodies, inflammation, and other classic immune reactions. Antibacterial vaccines have been responsible for a drastic reduction in global bacterial diseases. Vaccines made from attenuated whole cells or lysates have been replaced largely by less reactogenic, cell-free vaccines consisting of purified components, including capsular polysaccharides and their conjugates, to protein carriers, as well as inactivated toxins (toxoids) and proteins.
Silver mechanism of action includes disruption of multiple bacterial cellular processes (disulfide bond formation, metabolism, and iron homeostasis), which may lead to increased production of reactive oxygen species, and increased cell membrane permeability. In both mouse model and in vitro, evidence suggests that silver may increase the activity and potentially restore antibiotic susceptibility to antibiotic-resistant bacteria. In one study, silver-sensitized gram-negative bacteria in mouse and in vitro to vancomycin, "thereby expanding the antibacterial spectrum of this drug." Finally, "both in vitro and in a mouse biofilm infection model that silver can enhance antibacterial action against bacteria that produce biofilms."
Host defense peptides
An additional therapeutic agent is the enhancement of the multifunctional properties of natural anti-infectives, such as cationic host defense (antimicrobial) peptides (HDPs).
Functionalization of antimicrobial surfaces can be used for sterilization, self-cleaning, and surface protection.
Antimicrobial copper alloy surfaces
Copper-alloy surfaces have natural intrinsic properties to effectively and quickly destroy bacteria. The United States Environmental Protection Agency has approved the registration of 355 different antibacterial copper alloys that kill E. coli O157:H7, methicillin-resistant Staphylococcus aureus (MRSA), Staphylococcus, Enterobacter aerogenes, and Pseudomonas aeruginosa in less than 2 hours of contact. As a public hygienic measure in addition to regular cleaning, antimicrobial copper alloys are being installed in healthcare facilities and in a subway transit system.
Targeting the trans-translational pathway
Using high-throughput screening, researchers in Pennsylvania State University discovered 46 small molecules capable of disrupting the trans-translational pathway, the mechanism used by bacteria to facilitate protein synthesis and is unique to bacteria only. One of the most potent molecules, KKL-35, was found to cause cell death in Shigella, Bacillus anthracis, and Mycobacterium tuberculosis, and no resistant mutant strains were observed in the experiments. This result demonstrated that KKL-35 could be effective in a wide spectrum of bacterial species due to its targeted pathway and may represent a new class of antibiotics.
Status of new antibiotics development (2013)
In a policy report released by the Infectious Disease Society of America (IDSA) on April 2013, IDSA expressed grave concern over the weak pipeline of antibiotics to combat the growing ability of bacteria, especially the Gram-negative bacilli (GNB), to develop resistance to antibiotics. Since 2009, only 2 new antibiotics were approved in United States, and the number of new antibiotics annually approved for marketing continues to decline. The report could identify only seven antibiotics currently in phase 2 or phase 3 clinical trials to treat the GNB, which includes E. coli, Salmonella, Shigella, and the Enterobacteriaceae bacteria, and these drugs do not address the entire spectrum of the resistance developed by those bacteria. Some of these seven new antibiotics are combination of existent antibiotics, they include:
- Ceftolozane/tazobactam (CXA-201; CXA-101/tazobactam): Antipseudomonal cephalosporin/β-lactamase inhibitor combination (cell wall synthesis inhibitor). In phase 3.
- Ceftazidime/avibactam (ceftazidime/NXL104): Antipseudomonal cephalosporin/β-lactamase inhibitor combination (cell wall synthesis inhibitor). In phase 3.
- Ceftaroline/avibactam (CPT-avibactam; ceftaroline/NXL104): Anti-MRSA cephalosporin/ β-lactamase inhibitor combination (cell wall synthesis inhibitor)
- Imipenem/MK-7655: Carbapenem/ β-lactamase inhibitor combination (cell wall synthesis inhibitor). In phase 2.
- Plazomicin (ACHN-490): Aminoglycoside (protein synthesis inhibitor). In phase 2.
- Eravacycline (TP-434): A synthetic tetracycline derivative / protein synthesis inhibitor targeting the ribosome being developed by Tetraphase. Phase 2 trials complete.
- Brilacidin (PMX-30063): Peptide defense protein mimetic (cell membrane disruption). In phase 2.
The IDSA’s prognosis for sustainable R&D infrastructure for antibiotics development will depend upon clarification of FDA regulatory clinical trial guidance that would facilitate the speedy approval of new drugs, and the appropriate economic incentives for the pharmaceuticals companies to invest in this endeavor. On 12 December 2013, the Antibiotic Development to Advance Patient Treatment (ADAPT) Act of 2013 was introduced in the U.S. Congress. The ADAPT Act aims to fast track the drug development in order to combat the growing public health threat of 'superbugs'. Under this Act, FDA can approve antibiotics and antifungals needed for life-threatening infections based on data from smaller clinical trial. The CDC will reinforce the monitoring of the use of antibiotics that treat serious and life-threatening infections and the emerging resistance, and make the data publicly available. The FDA antibiotics labeling process, 'Susceptibility Test Interpretive Criteria for Microbial Organisms'’ or 'breakpoints' is also streamlined to allow the most up-to-date and cutting-edge data available to healthcare professionals under the new Act.
- "Dorlands Medical Dictionary:antibacterial". Archived from the original on 2010-11-17. Retrieved 29 October 2010.
- "Dorlands Medical Dictionary:antibiotic". Archived from the original on 2010-11-17. Retrieved 29 October 2010.
- SA Waksman (1947). "What Is an Antibiotic or an Antibiotic Substance?". Mycologia 39 (5): 565–569. doi:10.2307/3755196. JSTOR 3755196. PMID 20264541.
- von Nussbaum F. et al.; Brands, Michael; Hinzen, Berthold; Weigand, Stefan; Häbich, Dieter (2006). "Medicinal Chemistry of Antibacterial Natural Products – Exodus or Revival?". Angew. Chem. Int. Ed. 45 (31): 5072–5129. doi:10.1002/anie.200600350. PMID 16881035.
- Lindblad WJ (2008). "Considerations for Determining if a Natural Product Is an Effective Wound-Healing Agent". International Journal of Lower Extremity Wounds 7 (2): 75–81. doi:10.1177/1534734608316028. PMID 18483011.
- Forrest RD (March 1982). "Early history of wound treatment". J R Soc Med 75 (3): 198–205. PMC 1437561. PMID 7040656.
- Wainwright, Milton (1989). "Moulds in ancient and more recent medicine". Mycologist 3: 21. doi:10.1016/S0269-915X(89)80010-2.
- Kingston W (June 2008). "Irish contributions to the origins of antibiotics". Irish journal of medical science 177 (2): 87–92. doi:10.1007/s11845-008-0139-x. PMID 18347757.
- Calderon CB, Sabundayo BP (2007). Antimicrobial Classifications: Drugs for Bugs. In Schwalbe R, Steele-Moore L, Goodwin AC. Antimicrobial Susceptibility Testing Protocols. CRC Press. Taylor & Frances group. ISBN 978-0-8247-4100-6
- Foster W, Raoult A (December 1974). "Early descriptions of antibiosis". J R Coll Gen Pract 24 (149): 889–94. PMC 2157443. PMID 4618289.
- H. Landsberg (1949). "Prelude to the discovery of penicillin". Isis 40 (3): 225–227. doi:10.1086/349043.
- Limbird LE (December 2004). "The receptor concept: a continuing evolution". Mol. Interv. 4 (6): 326–36. doi:10.1124/mi.4.6.6. PMID 15616162.
- Bosch F, Rosich L (2008). "The contributions of Paul Ehrlich to pharmacology: a tribute on the occasion of the centenary of his Nobel Prize". Pharmacology 82 (3): 171–9. doi:10.1159/000149583. PMC 2790789. PMID 18679046.
- Fleming A (1980). "Classics in infectious diseases: on the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B. influenzae by Alexander Fleming, Reprinted from the British Journal of Experimental Pathology 10:226-236, 1929". Rev. Infect. Dis. 2 (1): 129–39. doi:10.1093/clinids/2.1.129. PMID 6994200.
- Sykes R (2001). "Penicillin: from discovery to product". Bull. World Health Organ. 79 (8): 778–9. PMC 2566502. PMID 11545336.
- Van Epps HL (2006). "René Dubos: unearthing antibiotics". J. Exp. Med. 203 (2): 259. doi:10.1084/jem.2032fta. PMC 2118194. PMID 16528813.
- HW Florey (1945). "Use of Micro-organisms for therapeutic purposes". Br Med J. 2 (4427): 635–642. doi:10.1136/bmj.2.4427.635. PMC 2060276. PMID 20786386.
- ἀντί, Henry George Liddell, Robert Scott, A Greek-English Lexicon, on Perseus
- βακτηρία, Henry George Liddell, Robert Scott, A Greek-English Lexicon, on Perseus
- bacterial, on Oxford Dictionaries
- , Henry George Liddell, Robert Scott, A Greek-English Lexicon, on Perseus
- βίωσις, Henry George Liddell, Robert Scott, A Greek-English Lexicon, on Perseus
- βίος, Henry George Liddell, Robert Scott, A Greek-English Lexicon, on Perseus
- Rogers RS, Seehafer JR, Perry HO (February 1982). "Treatment of cicatricial (benign mucous membrane) pemphigoid with dapsone". J. Am. Acad. Dermatol. 6 (2): 215–23. doi:10.1016/S0190-9622(82)70014-3. PMID 7037880.
- Wilson W, Taubert KA, Gewitz M, et al. (October 2007). "Prevention of infective endocarditis: guidelines from the American Heart Association". Circulation 116 (15): 1736–54. doi:10.1161/CIRCULATIONAHA.106.183095. PMID 17446442. "American Heart Association Rheumatic Fever"
- Zadik Y, Findler M, Livne S, et al. (December 2008). "Dentists' knowledge and implementation of the 2007 American Heart Association guidelines for prevention of infective endocarditis". Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology 106 (6): e16–9. doi:10.1016/j.tripleo.2008.08.009. PMID 19000604.
- Pankey GA, Sabath LD. (March 2004). "Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections". Clin Infect Dis. 38 (6): 864–870. doi:10.1086/381972. PMID 14999632.
- Mascio CT, Alder JD, Silverman JA (December 2007). "Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells". Antimicrob. Agents Chemother. 51 (12): 4255–60. doi:10.1128/AAC.00824-07. PMC 2167999. PMID 17923487.
- Pelczar, M.J., Chan, E.C.S. and Krieg, N.R. (1999) "Host-Parasite Interaction; Nonspecific Host Resistance", In: Microbiology Concepts and Applications, 6th ed., McGraw-Hill Inc., New York, U.S.A. pp. 478–479.
- Rhee KY, Gardiner DF (September 2004). "Clinical relevance of bacteriostatic versus bactericidal activity in the treatment of gram-positive bacterial infections". Clin. Infect. Dis. 39 (5): 755–6. doi:10.1086/422881. PMID 15356797.
- Wiegand I, Hilpert K, Hancock REW (January 2008). "Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC)of antimicrobial substances". Nature Protocols 3 (2): 163–175. doi:10.1038/nprot.2007.521. PMID 18274517.
- Spanu T, Santangelo R, Andreotti F, Cascio GL, Velardi G, Fadda G (February 2004). "Antibiotic therapy for severe bacterial infections: correlation between the inhibitory quotient and outcome". Int. J. Antimicrob. Agents 23 (2): 120–8. doi:10.1016/j.ijantimicag.2003.06.006. PMID 15013036.
- Sharma, K.K., Sangraula, H., Mediratta, P.K. (December 2002). "Some new concepts in antibacterial drug therapy" (PDF). Indian Journal of Pharmacology 34 (6): 390–396. Retrieved 13 November 2008.
- Finberg RW, Moellering RC, Tally FP, et al. (November 2004). "The importance of bactericidal drugs: future directions in infectious disease". Clin. Infect. Dis. 39 (9): 1314–20. doi:10.1086/425009. PMID 15494908.
- Cunha BA. Antibiotic Essentials 2009. Jones & Bartlett Learning, ISBN 978-0-7637-7219-2 p. 180, for example.
- Srivastava, Aashish; Talaue, Meliza; Liu, Shuang; Degen, David; Ebright, Richard Y; Sineva, Elena; Chakraborty, Anirban; Druzhinin, Sergey Y; Chatterjee, Sujoy; Mukhopadhyay, Jayanta; Ebright, Yon W; Zozula, Alex; Shen, Juan; Sengupta, Sonali; Niedfeldt, Rui Rong; Xin, Cai; Kaneko, Takushi; Irschik, Herbert; Jansen, Rolf; Donadio, Stefano; Connell, Nancy; Ebright, Richard H (2011). "New target for inhibition of bacterial RNA polymerase: 'switch region'". Current Opinion in Microbiology 14 (5): 532–43. doi:10.1016/j.mib.2011.07.030. PMC 3196380. PMID 21862392.
- William Andrew Publishing (2013). Pharmaceutical Manufacturing Encyclopedia. Elsevier Science. p. 305.
- Slama TG, Amin A, Brunton SA, et al. (July 2005). "A clinician's guide to the appropriate and accurate use of antibiotics: the Council for Appropriate and Rational Antibiotic Therapy (CARAT) criteria". Am. J. Med. 118 Suppl 7A (7): 1S–6S. doi:10.1016/j.amjmed.2005.05.007. PMID 15993671.
- University of Michigan Health System: Antibiotic-Associated Diarrhea, November 26, 2006[dead link]
- Pirotta MV, Garland SM (2006). "Genital Candida species detected in samples from women in Melbourne, Australia, before and after treatment with antibiotics". J Clin Microbiol. 44 (9): 3213–3217. doi:10.1128/JCM.00218-06. PMC 1594690. PMID 16954250.
- Thacker, James D. (2012). "The law of unintended consequences and antibiotics". Open Journal of Immunology 02 (2): 59. doi:10.4236/oji.2012.22007.
- "Antibiotics and Chronic Liver Diseases".
- Weaver K, Glasier A (February 1999). "Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill. A literature review". Contraception 59 (2): 71–8. doi:10.1016/S0010-7824(99)00009-8. PMID 10361620.
- Weisberg E (May 1999). "Interactions between oral contraceptives and antifungals/antibacterials. Is contraceptive failure the result?". Clin Pharmacokinet 36 (5): 309–13. doi:10.2165/00003088-199936050-00001. PMID 10384856.
- Hassan T (March 1987). "Pharmacologic considerations for patients taking oral contraceptives". Conn Dent Stud J 7: 7–8. PMID 3155374.
- Orme ML, Back DJ (December 1990). "Factors affecting the enterohepatic circulation of oral contraceptive steroids". Am. J. Obstet. Gynecol. 163 (6 Pt 2): 2146–52. doi:10.1016/0002-9378(90)90555-L. PMID 2256523. Archived from the original on 2010-11-17.
- Lwanga, J; Mears, A; Bingham, J S; Bradbeer, C S (2008). "Do antibiotics and alcohol mix? The beliefs of genitourinary clinic attendees". BMJ 337: a2885. doi:10.1136/bmj.a2885.
- "antibiotics-and-alcohol". Archived from the original on 2010-11-17., Mayo Clinic
- "Can I drink alcohol while taking antibiotics?". NHS Direct (UK electronic health service). Archived from the original on 2010-11-17. Retrieved 17 February 2008.
- "Antibiotics FAQ". McGill University, Canada. Archived from the original on February 16, 2008. Retrieved 17 February 2008.
- Stockley, IH (2002), Stockley's Drug Interactions. 6th ed. London: Pharmaceutical Press.[page needed]
- Levy SB (October 1994). "Balancing the drug-resistance equation". Trends Microbiol. 2 (10): 341–2. doi:10.1016/0966-842X(94)90607-6. PMID 7850197.
- Luria SE, Delbrück M (November 1943). "Mutations of Bacteria from Virus Sensitivity to Virus Resistance". Genetics 28 (6): 491–511. PMC 1209226. PMID 17247100. Archived from the original on 2010-11-17.
- Pearson, Carol (2007-02-28). "Antibiotic Resistance Fast-Growing Problem Worldwide". Voice Of America. Archived from the original on 2 December 2008. Retrieved 29 December 2008.[dead link]
- Topp, E; Chapman, R; Devers-Lamrani, M; Hartmann, A; Marti, R; Martin-Laurent, F; Sabourin, L; Scott, A; Sumarah, M (2013). "Accelerated Biodegradation of Veterinary Antibiotics in Agricultural Soil following Long-Term Exposure, and Isolation of a Sulfamethazine-degrading Microbacterium sp". Journal of Environmental Quality 42 (1): 173–178. doi:10.2134/jeq2012.0162. PMID 23673752.
- Witte W (September 2004). "International dissemination of antibiotic resistant strains of bacterial pathogens". Infect. Genet. Evol. 4 (3): 187–91. doi:10.1016/j.meegid.2003.12.005. PMID 15450197.
- Dyer, Betsey Dexter (2003). A Field Guide To Bacteria. Cornell University Press. pp. Chapter 9, Pathogens. ISBN 978-0-8014-8854-2.
- Andersson DI (October 2006). "The biological cost of mutational antibiotic resistance: any practical conclusions?". Current Opinion in Microbiology 9 (5): 461–5. doi:10.1016/j.mib.2006.07.002. PMID 16890008.
- D'Costa VM, King CE, Kalan L, Morar M, Sung WW, Schwarz C, Froese D, Zazula G, Calmels F, Debruyne R, Golding GB, Poinar HN, Wright GD (August 2011). "Antibiotic resistance is ancient". Nature 477 (7365): 457–61. doi:10.1038/nature10388. PMID 21881561.
- Gladki A, Kaczanowski S, Szczesny P, Zielenkiewicz P (February 2013). "The evolutionary rate of antibacterial drug targets". BMC Bioinformatics 14: 36. doi:10.1186/1471-2105-14-36. PMC 3598507. PMID 23374913.
- Alekshun MN, Levy SB (March 2007). "Molecular mechanisms of antibacterial multidrug resistance". Cell 128 (6): 1037–50. doi:10.1016/j.cell.2007.03.004. PMID 17382878.
- Marshall CG, Lessard IA, Park I, Wright GD (September 1998). "Glycopeptide antibiotic resistance genes in glycopeptide-producing organisms". Antimicrob. Agents Chemother. 42 (9): 2215–20. PMC 105782. PMID 9736537. Archived from the original on 2010-11-17.
- Nikaido H (February 2009). "Multidrug Resistance in Bacteria". Annu. Rev. Biochem. 78: 119–46. doi:10.1146/annurev.biochem.78.082907.145923. PMC 2839888. PMID 19231985.
- Baker-Austin C, Wright MS, Stepanauskas R, McArthur JV (April 2006). "Co-selection of antibiotic and metal resistance". Trends Microbiol. 14 (4): 176–82. doi:10.1016/j.tim.2006.02.006. PMID 16537105.
- "Health ministers to accelerate efforts against drug-resistant TB". World Health Organization (WHO).
- Boseley, Sarah (2010-08-12). "Are you ready for a world without antibiotics?". The Guardian (London). Archived from the original on 2010-11-17.
- "Health Protection Report". Health Protection Agency. 3 July 2009. Archived from the original on 2010-11-17.
- Marino PL (2007). "Antimicrobial therapy". The ICU book. Hagerstown, MD: Lippincott Williams & Wilkins. p. 817. ISBN 978-0-7817-4802-5.
- Larson E (2007). "Community factors in the development of antibiotic resistance". Annu Rev Public Health 28: 435–447. doi:10.1146/annurev.publhealth.28.021406.144020. PMID 17094768.
- Hawkey PM (September 2008). "The growing burden of antimicrobial resistance". J. Antimicrob. Chemother. 62 Suppl 1: i1–9. doi:10.1093/jac/dkn241. PMID 18684701.
- Ong S, Nakase J, Moran GJ, Karras DJ, Kuehnert MJ, Talan DA (2007). "Antibiotic use for emergency department patients with upper respiratory infections: prescribing practices, patient expectations, and patient satisfaction". Annals of Emergency Medicine 50 (3): 213–20. doi:10.1016/j.annemergmed.2007.03.026. PMID 17467120.
- Metlay JP, Camargo CA, MacKenzie T, et al. (2007). "Cluster-randomized trial to improve antibiotic use for adults with acute respiratory infections treated in emergency departments". Annals of Emergency Medicine 50 (3): 221–30. doi:10.1016/j.annemergmed.2007.03.022. PMID 17509729.
- "." Centers for Disease Control and Prevention. Retrieved 12 March 2009.
- "Keep Antibiotics Working". Keep Antibiotics Working. Archived from the original on 2010-11-17. Retrieved 21 May 2010.
- Sabuncu E, David J, Bernède-Bauduin C et al. (2009). "Significant reduction of antibiotic use in the community after a nationwide campaign in France, 2002–2007". In Klugman, Keith P. PLoS Med 6 (6): e1000084. doi:10.1371/journal.pmed.1000084. PMC 2683932. PMID 19492093. Archived from the original on 2010-11-17.
- (accessed Nov 12, 2008)
- GovTrack.us. S. 742--109th Congress (2005): Preservation of Antibiotics for Medical Treatment Act of 2005, GovTrack.us (database of federal legislation) <http://www.govtrack.us/congress/bill.xpd?bill=s109-742> (accessed Nov 12, 2008)
- GovTrack.us. H.R. 2562--109th Congress (2005): Preservation of Antibiotics for Medical Treatment Act of 2005, GovTrack.us (database of federal legislation) <http://www.govtrack.us/congress/bill.xpd?bill=h109-2562> (accessed Nov 12, 2008)
- (accessed Nov 12, 2008)
- John Gever (March 23, 2012). "FDA Told to Move on Antibiotic Use in Livestock". MedPage Today. Retrieved 24 March 2012.
- Marquez, Béatrice (2005). "Bacterial efflux systems and efflux pumps inhibitors". Biochimie 87 (12): 1137–47. doi:10.1016/j.biochi.2005.04.012. PMID 15951096.
- Allison, Kyle R.; Brynildsen, Mark P.; Collins, James J. (2011). "Metabolite-enabled eradication of bacterial persisters by aminoglycosides". Nature 473 (7346): 216–20. doi:10.1038/nature10069. PMC 3145328. PMID 21562562.
- Abedon ST, Calendar RL, ed. (2005). The Bacteriophages.
- Mattey M, Spencer J (December 2008). "Bacteriophage therapy--cooked goose or phoenix rising?". Current Opinion in Biotechnology 19 (6): 608–12. doi:10.1016/j.copbio.2008.09.001. PMID 18926909.
- Stephen T. Abedon (Editor) (2008). Abedon ST, ed. Bacteriophage Ecology: Population Growth, Evolution and Impact of Bacterial Viruses. Cambridge: Cambridge University Press. ISBN 978-0-521-85845-8.
- Kutateladze M, Adamia R (August 2008). "Phage therapy experience at the Eliava Institute". Med Mal Infect 38 (8): 426–30. doi:10.1016/j.medmal.2008.06.023. PMID 18687542.
- Merril CR, Scholl D, Adhya SL (June 2003). "The prospect for bacteriophage therapy in Western medicine". Nature Reviews Drug Discovery 2 (6): 489–97. doi:10.1038/nrd1111. PMID 12776223.
- Abuladze T, Li M, Menetrez MY, Dean T, Senecal A, Sulakvelidze A (October 2008). "Bacteriophages reduce experimental contamination of hard surfaces, tomato, spinach, broccoli, and ground beef by Escherichia coli O157:H7". Appl. Environ. Microbiol. 74 (20): 6230–8. doi:10.1128/AEM.01465-08. PMC 2570303. PMID 18723643.
- Thiel K (January 2004). "Old dogma, new tricks--21st Century phage therapy". Nat. Biotechnol. 22 (1): 31–6. doi:10.1038/nbt0104-31. PMID 14704699.
- Parfitt T (2005). "Georgia: an unlikely stronghold for bacteriophage therapy". Lancet 365 (9478): 2166–7. doi:10.1016/S0140-6736(05)66759-1. PMID 15986542.
- Lu TK, Collins JJ (2007). "Dispersing biofilms with engineered enzymatic bacteriophage". Proceedings of the National Academy of Sciences of the United States of America 104 (27): 11197–11202. doi:10.1073/pnas.0704624104. PMC 1899193. PMID 17592147.
- Williams SR, Gebhart D, Martin DW, Scholl D (2008). "Retargeting R-type pyocins to generate novel bactericidal protein complexes". Applied and Environmental Microbiology 74 (12): 3868–3876. doi:10.1128/AEM.00141-08. PMC 2446544. PMID 18441117.
- Gillor O, Nigro LM, Riley MA (2005). "Genetically engineered bacteriocins and their potential as the next generation of antimicrobials". Curr. Pharm. Des. 11 (8): 1067–75. doi:10.2174/1381612053381666. PMID 15777256.
- Gillor O, Kirkup BC, Riley MA (2004). "Colicins and microcins: the next generation antimicrobials". Adv. Appl. Microbiol. Advances in Applied Microbiology 54: 129–46. doi:10.1016/S0065-2164(04)54005-4. ISBN 978-0-12-002656-2. PMID 15251279.
- Kirkup BC (2006). "Bacteriocins as oral and gastrointestinal antibiotics: theoretical considerations, applied research, and practical applications". Curr. Med. Chem. 13 (27): 3335–50. doi:10.2174/092986706778773068. PMID 17168847.
- Jones RL, Peterson CM, Grady RW, Kumbaraci T, Cerami A, Graziano JH (1977). "Effects of iron chelators and iron overload on Salmonella infection". Nature 267 (5606): 63–65. doi:10.1038/267063a0. PMID 323727.
- Soteriadou K, Papvassiliou P, Voyiatzaki C, Boelaert J (1995). "Effects of iron chelation on the in-vitro growth of leishmania promastigotes". The Journal of antimicrobial chemotherapy 35 (1): 23–29. doi:10.1093/jac/35.1.23. PMID 7768775.
- Brock JH, Liceaga J, Kontoghiorghes GJ (2006). "The effect of synthetic iron chelators on bacterial growth in human serum". FEMS Microbiology Letters 47 (1): 55–60. doi:10.1111/j.1574-6968.1988.tb02490.x.
- Miller, AA; Miller, PF (editor) (2011). Emerging Trends in Antibacterial Discovery: Answering the Call to Arms. Caister Academic Press. ISBN 978-1-904455-89-9.[page needed]
- Nacar A, Nacar E (2008). "Phagotrophic protozoa: A new weapon against pathogens?". Medical Hypotheses 70 (1): 141–142. doi:10.1016/j.mehy.2007.03.037. PMID 17553625.
- Ljungh A, Wadstrom T (editors) (2009). Lactobacillus Molecular Biology: From Genomics to Probiotics. Caister Academic Press. ISBN 978-1-904455-41-7.
- Morones-Ramirez, J. R.; Winkler, J. A.; Spina, C. S.; Collins, J. J. (2013). "Silver Enhances Antibiotic Activity Against Gram-Negative Bacteria". Science Translational Medicine 5 (190): 190ra81. doi:10.1126/scitranslmed.3006276. PMC 3771099. PMID 23785037.
- A. Samuel (July 22, 2011). "Chilean subway protected with antimicrobial copper". Rail News (rail.co). Retrieved 19 October 2012.
- "PR 811 Chilean subway installs antimicrobial copper" (PDF) (Press release). Retrieved 19 October 2012.
- "New kind of antibiotic may be more effective at fighting tuberculosis, anthrax, and other diseases" (Press release). Pennsylvania State University. 7 June 2013. Retrieved 11 June 2013.
- Ramadoss, N. S.; Alumasa, J. N.; Cheng, L.; Wang, Y.; Li, S.; Chambers, B. S.; Chang, H.; Chatterjee, A. K.; Brinker, A.; Engels, I. H.; Keiler, K. C. (2013). "Small molecule inhibitors of trans-translation have broad-spectrum antibiotic activity". Proceedings of the National Academy of Sciences 110 (25): 10282. doi:10.1073/pnas.1302816110.[non-primary source needed]
- Steenhuysen, Julie (18 April 2013). "Drug pipeline for worst superbugs ‘on life support’: report". Reuters. Retrieved 23 June 2013.
- Boucher, H. W.; Talbot, G. H.; Benjamin Jr, D. K.; Bradley, J.; Guidos, R. J.; Jones, R. N.; Murray, B. E.; Bonomo, R. A.; Gilbert, D.; Infectious Diseases Society of America (2013). "10 x '20 Progress--Development of New Drugs Active Against Gram-Negative Bacilli: An Update from the Infectious Diseases Society of America". Clinical Infectious Diseases 56 (12): 1685–94. doi:10.1093/cid/cit152. PMC 3707426. PMID 23599308.
- Stynes, T. Tetraphase Pharma's Eravacycline Gets Qualified-Infectious-Disease-Product Status. Wall Street J. Monday, July 15, 2013.
- Press Release (12 December 2013). "Green, Gingrey Introduce ADAPT Act to Safeguard Public Health". U.S .Congress.
- "Antibiotic Development to Advance Patient Treatment Act of 2013". U.S. Congress. 12 December 2013.
|Wikimedia Commons has media related to Antibiotics.|